References
- Miller TM, Cudkowicz ME, Genge A. et al. N Engl J Med. 2022;387(12):1099–1110.
- Forsberg K, Jonsson PA, Andersen PM, Bergemalm D, Graffmo KS. et al. PLoS One. 2010;5(7)e11552.
References
- Post J, Schaffrath A, GeringI, et al. Oral treatment with RD2RD2 impedes development of motoric phenotype and delays symptom onset in SOD1G93A transgenic mice. Int J Mol Sci. 2021;22(13):7066.
- Wintz K, Post J, Langen K-J, et al. Oral treatment with D-RD2RD2 impedes early disease mechanisms in SOD1* G93A transgenic mice but does not prolong survival. Biomedicines. 2023;11(4):995.
References
- Lemarchant S, Sourioux M, Le DouceJ, et al. Int J Mol Sci. 2022;23(16):8867.
- Le Douce J, Delétage N, Bourdès V, et al. Front Neurosci. 2021;15:651094.
References
- HammerRP, TomiyasuU and SheibelAB. Exp.Neurol. 1979;63:336–46.
- KatoT, HiranoA. Donnenfeld H Ann Neurol. 1984;16: 305–13.
- SephtonCF, TangAA, KulkarniA, et al. PNAS. 2014;111(44):E4769–78.
- ThammisettySS, RenaudL, Picher-MartelV, et al. Neurotherapeutics. 2021;18(2):1095–112.
References
- Majid T, Griffin D, CrissII Z et al. Alzheimer's & Dementia: Transl Res Clin Interven. 2015;1(3):170–81.
- Shen S, Kozikowski AP. Expert Opin Ther Patents, 2020;30(2):121–36.
Reference
- Gatto N, Dos Santos Souza C, Shaw AC, et al. Aging Cell. 2021;20(1):e13281.
References
- Brosius Lutz A, Barres BA. Dev Cell. 2014;28:7–1.
- Negro S, Lessi F, Duregotti E. et al. EMBO Mol Med. 2017;9:1000–10.
- Negro S, Zanetti G, Mattarei A. et al. Cells. 2019;8(10):1183.
- Zanetti G, Negro S, Megighian A, Mattarei A, Lista F, Fillo S. et al. Ann Clin Transl Neurol. 2019;6:2395–402.
- Fischer LR, Culver DG, Tennant P. et al. Exp Neurol. 2004;185:232–40.
- Dadon-Nachum M, Melamed E, Offen D, J Mol Neurosci. 2011;43:470–7.
- Martineau È, Di Polo A Vande Velde C, Robitaille R. et al. Elife. 2018;7:e41973.
- Mishra RK, Shum A, Platanias L. et al. Sci Rep. 2016;6:30155.
References
- Martineau É, Di Polo A, Vande Velde C, Robitaille R. eLife. 2018;7:e41973.
- Arbour D, Tremblay E, Martineau É et al. J Neurosci. 2015;35(2):688–706.
- Perez-Gonzalez AP, Provost F, RousseI et al. Glia. 2022;70(9):1605–29.
References
- Batulan Z, Shinder GA, Minotti S. et al. J Neurosci. 2003;23:5789.
- Chen S, Brown IR. Cell Stress Chaperones. 2007;12:51.
References
- Renton AE, Majounie E, Waite A, et al. Neuron. 2011;72(2): 257–68.
- Mori K, Weng SM, Arzberger T, et al. Science. 2013;339(6125):1335–8.
- Smeyers J, Banchi EG, Latouche M. Front Cell Neurosci. 2021;15:661447.
- Babić Leko M, Župunski V, Kirincich J, et al. Behaviour Neurol. 2019;2019:2909168.
- Lagier-Tourenne C, Baughn M, Rigo F, et al. Proc Natl Acad Sci. 2013;110(47):E4530–E9.
References
- Hasan R, Humphrey J, Bettencourt C, et al. Acta Neuropathol. 2022;143:383–401.
- Umoh ME, Dammer EB, Dai J, et al. EMBO Mol Med. 2018;10:48–62.
- San Gil R, Pascovici D, Venturato J, et al. Biorxiv. 2023; 2023.06.21.546009.
References
- Dubowsky M, Theunnisen F, Carr JM, et al. Mol Neurobiol. 2023; 60:6330–6345.
- Gold J, Rowe D, Kiernan M, et al. Amyotrophic lateral sclerosis frontotemporal degeneration, 2019;20(7–8):595–604.
- Walker A, Spiller K, Guanghui G, et al. Acta Neuropathologica. 2015;130(5):643–660.
References
- Le Masson G, Przedborski S, Abbott LF. A computational model of motor neuron degeneration. Neuron. 2014;83(4):975 88.
- Szelechowski M, Bétourné A, Monnet Y, et al. A viral peptide that targets mitochondria protects against neuronal degeneration in models of Parkinson’s disease. Nat Commun. 2014;5(1):5181.
- Poenisch M, Burger N, Staeheli P, et al. Protein X of Borna disease virus inhibits apoptosis and promotes viral persistence in the central nervous systems of newborn-infected rats. J Virol. 2009;83(9):4297–307.
Reference
- Celeste D, Miller M. Cytokine. 2018;108:173–8.